Literature DB >> 19723040

eEF1A2 as a putative oncogene.

Mee-Hyun Lee1, Young-Joon Surh.   

Abstract

The first evidence for the role of the protein elongation factor eEF1A2 in tumorigenesis was reported by Anand and colleagues who demonstrated that eEF1A2 is overexpressed in about 30% of ovarian tumors and some established ovarian cancer cells. This abnormal expression correlates with a poor prognosis. Since this discovery, there have been several reports suggesting eEF1A2 as a diagnostic marker in various cancers. This review highlights the oncogenic potential of eEF1A2.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19723040     DOI： 10.1111/j.1749-6632.2009.04909.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  21 in total

1.  METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.

Authors:  Shuo Liu; Simone Hausmann; Scott Moore Carlson; Mary Esmeralda Fuentes; Joel William Francis; Renjitha Pillai; Shane Michael Lofgren; Laura Hulea; Kristofferson Tandoc; Jiuwei Lu; Ami Li; Nicholas Dang Nguyen; Marcello Caporicci; Michael Paul Kim; Anirban Maitra; Huamin Wang; Ignacio Ivan Wistuba; John Anthony Porco; Michael Cory Bassik; Joshua Eric Elias; Jikui Song; Ivan Topisirovic; Capucine Van Rechem; Pawel Karol Mazur; Or Gozani
Journal:  Cell       Date:  2019-01-03       Impact factor: 41.582

2.  Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells.

Authors:  Todd A Stueckle; Yongju Lu; Mary E Davis; Liying Wang; Bing-Hua Jiang; Ida Holaskova; Rosana Schafer; John B Barnett; Yon Rojanasakul
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-13       Impact factor: 4.219

3.  Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorer prognosis in patients with gastric cancer.

Authors:  Song Yang; Mingdian Lu; Yuanyuan Chen; Delong Meng; Ruochuan Sun; Dapeng Yun; Zhijie Zhao; Daru Lu; Yongxiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-20       Impact factor: 4.553

4.  [EEFSEC knockdown inhibits proliferation, migration and invasion of prostate cancer cells in vitro].

Authors:  B Xu; J Hao; Q Xie; N Sa; S Wang; X DU; H Lu; P Gao; G Shi; X Dong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-12-20

5.  Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.

Authors:  Mee-Hyun Lee; Bu Young Choi; Yong-Yeon Cho; Sung-Young Lee; Zunnan Huang; Joydeb Kumar Kundu; Myoung Ok Kim; Dong Joon Kim; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  J Cell Sci       Date:  2013-02-26       Impact factor: 5.285

Review 6.  Translation Elongation and Recoding in Eukaryotes.

Authors:  Thomas E Dever; Jonathan D Dinman; Rachel Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-08-01       Impact factor: 10.005

Review 7.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

8.  Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Authors:  Stine H Kresse; Halfdan Rydbeck; Magne Skårn; Heidi M Namløs; Ana H Barragan-Polania; Anne-Marie Cleton-Jansen; Massimo Serra; Knut Liestøl; Pancras C W Hogendoorn; Eivind Hovig; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells.

Authors:  C Sanges; C Scheuermann; R P Zahedi; A Sickmann; A Lamberti; N Migliaccio; A Baljuls; M Marra; S Zappavigna; J Reinders; U Rapp; A Abbruzzese; M Caraglia; P Arcari
Journal:  Cell Death Dis       Date:  2012-03-01       Impact factor: 8.469

10.  Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744.

Authors:  A Vislovukh; G Kratassiouk; E Porto; N Gralievska; C Beldiman; G Pinna; A El'skaya; A Harel-Bellan; B Negrutskii; I Groisman
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.